NASDAQ:RGNX REGENXBIO (RGNX) Stock Price, News & Analysis $8.59 -0.25 (-2.83%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About REGENXBIO Stock (NASDAQ:RGNX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get REGENXBIO alerts:Sign Up Key Stats Today's Range$8.57▼$8.9850-Day Range$8.84▼$12.9552-Week Range$8.56▼$28.80Volume501,705 shsAverage Volume593,309 shsMarket Capitalization$423.11 millionP/E RatioN/ADividend YieldN/APrice Target$35.45Consensus RatingModerate Buy Company OverviewREGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.Read More… War on Elon Escalates… (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. REGENXBIO Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks92nd Percentile Overall ScoreRGNX MarketRank™: REGENXBIO scored higher than 92% of companies evaluated by MarketBeat, and ranked 119th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingREGENXBIO has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageREGENXBIO has only been the subject of 4 research reports in the past 90 days.Read more about REGENXBIO's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for REGENXBIO are expected to grow in the coming year, from ($4.66) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of REGENXBIO is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of REGENXBIO is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioREGENXBIO has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about REGENXBIO's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.13% of the outstanding shares of REGENXBIO have been sold short.Short Interest Ratio / Days to CoverREGENXBIO has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in REGENXBIO has recently decreased by 6.03%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldREGENXBIO does not currently pay a dividend.Dividend GrowthREGENXBIO does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.82 Percentage of Shares Shorted10.13% of the outstanding shares of REGENXBIO have been sold short.Short Interest Ratio / Days to CoverREGENXBIO has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in REGENXBIO has recently decreased by 6.03%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment0.45 News SentimentREGENXBIO has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for REGENXBIO this week, compared to 4 articles on an average week.Search Interest3 people have searched for RGNX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows6 people have added REGENXBIO to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, REGENXBIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $354,651.00 in company stock.Percentage Held by Insiders13.13% of the stock of REGENXBIO is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.08% of the stock of REGENXBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about REGENXBIO's insider trading history. Receive RGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address RGNX Stock News HeadlinesArgeris N. Karabelas Sells 10,000 Shares of REGENXBIO Inc. (NASDAQ:RGNX) StockOctober 3, 2024 | insidertrades.comREGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational HighlightsOctober 30 at 7:05 AM | prnewswire.comtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.October 31, 2024 | Traders Agency (Ad)REGENXBIO Inc. (NASDAQ:RGNX) Receives $35.45 Consensus Price Target from AnalystsOctober 28 at 3:36 AM | americanbankingnews.comThe past five years for REGENXBIO (NASDAQ:RGNX) investors has not been profitableOctober 24, 2024 | uk.finance.yahoo.comREGENXBIO's (RGNX) "Buy" Rating Reiterated at Chardan CapitalOctober 24, 2024 | americanbankingnews.comRegenxbio presents positive Phase 2 data of ABBV-RGX-314 in wet AMDOctober 21, 2024 | markets.businessinsider.comREGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024October 21, 2024 | prnewswire.comSee More Headlines RGNX Stock Analysis - Frequently Asked Questions How have RGNX shares performed this year? REGENXBIO's stock was trading at $17.95 on January 1st, 2024. Since then, RGNX stock has decreased by 51.8% and is now trading at $8.66. View the best growth stocks for 2024 here. How were REGENXBIO's earnings last quarter? REGENXBIO Inc. (NASDAQ:RGNX) released its quarterly earnings results on Thursday, August, 1st. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.24. The company's quarterly revenue was up 11.6% compared to the same quarter last year. Who are REGENXBIO's major shareholders? Top institutional investors of REGENXBIO include Assenagon Asset Management S.A. (1.13%), Hennion & Walsh Asset Management Inc. (0.31%), Harbor Capital Advisors Inc. (0.07%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Kenneth T Mills, Kenneth T Mills, Curran Simpson, Vittal Vasista, Steve Pakola, Argeris N Karabelas and Allan M Fox. View institutional ownership trends. How do I buy shares of REGENXBIO? Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of REGENXBIO own? Based on aggregate information from My MarketBeat watchlists, some other companies that REGENXBIO investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY) and Humana (HUM). Company Calendar Last Earnings8/01/2024Today10/31/2024Next Earnings (Confirmed)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RGNX CUSIPN/A CIK1590877 Webwww.regenxbio.com Phone(240) 552-8181FaxN/AEmployees344Year FoundedN/APrice Target and Rating Average Stock Price Target$35.45 High Stock Price Target$52.00 Low Stock Price Target$18.00 Potential Upside/Downside+309.4%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($5.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-263,490,000.00 Net Margins-270.74% Pretax Margin-270.91% Return on Equity-68.21% Return on Assets-40.07% Debt Debt-to-Equity RatioN/A Current Ratio3.53 Quick Ratio3.53 Sales & Book Value Annual Sales$89.04 million Price / Sales4.79 Cash FlowN/A Price / Cash FlowN/A Book Value$7.09 per share Price / Book1.22Miscellaneous Outstanding Shares49,256,000Free Float42,934,000Market Cap$426.56 million OptionableOptionable Beta1.21 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:RGNX) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding REGENXBIO Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share REGENXBIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.